US FTC Takes Aim at Pharmaceutical Rebates
FTC May Issue Policy Statement on Rebates, Fees for Excluding Lower Cost Drug Products Pharma Cos. Should Consider Reviewing Rebate Contracts with 6 PBMs in Advance
Amgen Inc. v. Sanofi: Does the Supreme Court’s Call for the Solicitor General’s Views Signal an Intention to Resolve Important Enablement Questions for Genus Claims?